Management of Extended-Spectrum Beta-Lactamase (ESBL) Urinary Tract Infections

Classification and Diagnostic Approach

ESBL-producing organisms are specifically listed as a factor associated with complicated UTIs, requiring special management considerations, according to the European Urology guidelines 1
Urine culture and susceptibility testing should be performed before initiating antimicrobial therapy to guide targeted treatment, as recommended by the European Urology and World Journal of Emergency Surgery guidelines 1, 2

For complicated UTIs, including those caused by ESBL producers, 7-14 days of treatment is generally recommended by the European Urology guidelines 1
Treatment can be shortened to 7 days when the patient is hemodynamically stable and has been afebrile for at least 48 hours, according to the European Urology guidelines 1

Management of any underlying urological abnormality or complicating factor is mandatory for successful treatment, as recommended by the European Urology guidelines 1

Initial broad-spectrum coverage should be narrowed based on culture results and susceptibility testing, according to the World Journal of Emergency Surgery guidelines 2
Short-course therapy (3-5 days) with early re-evaluation is recommended when adequate source control is achieved, as suggested by the World Journal of Emergency Surgery guidelines 2

Failing to obtain cultures before starting antibiotics is a common pitfall, as warned by the European Urology and World Journal of Emergency Surgery guidelines 1, 2
Continuing broad-spectrum therapy despite availability of susceptibility results is another pitfall to avoid, according to the World Journal of Emergency Surgery guidelines 2
Inadequate treatment duration, especially for complicated infections, should be avoided, as recommended by the European Urology guidelines 1
Neglecting to address underlying structural or functional abnormalities is a pitfall to avoid, according to the European Urology guidelines 1